Long-term safety of abatacept in patients with rheumatoid arthritis

Fabiola Atzeni, Piercarlo Sarzi-Puttini, Alessandra Mutti, Serena Bugatti, Lorenzo Cavagna, Roberto Caporali

Research output: Contribution to journalArticlepeer-review


Abatacept is a selective T cell co-stimulation modulator that was first approved by the Italian Medicines Agency and reimbursed by the Italian National Health Service when used to treat active rheumatoid arthritis "not sufficiently responsive to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one TNF inhibitor", and is now also approved as a first line biological agent. The aim of this review is to summarise the safety data collected in clinical trials and observational studies.

Original languageEnglish
Pages (from-to)1115-1117
Number of pages3
JournalAutoimmunity Reviews
Issue number12
Publication statusPublished - Oct 2013


  • Abatacept
  • Rheumatoid arthritis
  • Safety

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Long-term safety of abatacept in patients with rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this